• Fri, March 29, 2019
  • Mon, April 1, 2019
  • Tue, April 2, 2019

Alethia Young Maintained (ASND) at Buy with Decreased Target to $139 on, Mar 29th, 2019

Alethia Young of Credit Suisse, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Decreased Target from $151 to $139 on, Mar 29th, 2019.

Alethia has made no other calls on ASND in the last 4 months.



There is 1 other peer that has a rating on ASND. Out of the 1 peers that are also analyzing ASND, 0 agree with Alethia's Rating of Hold.



This is the rating of the analyst that currently disagrees with Alethia


  • Joseph Schwartz of "Leerink Swann" Upgraded from Hold to Buy and Increased Target to $90 on, Thursday, January 24th, 2019

Like: 👍